| TTM
|
12/31/2022
|
12/31/2021
|
|
|---|---|---|---|
| Total Revenue
|
80 | 5,325 | 5,514 |
| Selling, General and Administrative Expenses
|
-10,852 | -15,883 | -20,065 |
|
Research and Development Expenses
|
-29,980 | -65,031 | -71,080 |
| Depreciation, Amortization and Depletion
|
-1,010 | -1,420 | -1,427 |
| Other Income/Expense, Operating
|
0 | 0 | 0 |
|
Operating Income/Expenses
|
-41,842 | -82,334 | -92,572 |
|
Total Operating Profit/Loss
|
-41,762 | -77,009 | -87,058 |
| Net Investment Income
|
4,197 | 4,197 | 0 |
|
Other Income/Expense, Non-Operating
|
58 | 278 | 103 |
|
Non-Operating Income/Expenses, Total
|
4,255 | 4,475 | 103 |
|
Pretax Income
|
-37,507 | -72,534 | -86,955 |
|
Net Income from Continuing Operations
|
-37,507 | -72,534 | -86,955 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-37,507 | -72,534 | -86,955 |
|
Net Income after Non-Controlling/Minority Interests
|
-37,507 | -72,534 | -86,955 |
|
Net Income Available to Common Stockholders
|
-37,507 | -72,534 | -86,955 |
|
Diluted Net Income Available to Common Stockholders
|
-37,507 | -72,534 | -86,955 |
| Basic EPS
|
-1.99 | -6.07 | -9.69 |
| Diluted EPS
|
-1.99 | -6.07 | -9.69 |
|
Basic Weighted Average Shares Outstanding
|
19,826 | 11,945 | 8,971 |
|
Diluted Weighted Average Shares Outstanding
|
19,826 | 11,945 | 8,971 |
| Income Statement, Supplemental
|
|||
|
EBIT
|
-37,507 | -72,534 | -86,955 |
|
EBITDA
|
-36,497 | -71,114 | -85,528 |
|
Normalized EBITDA
|
-24,021 | -61,900 | -76,972 |
|
Normalized Income
|
-25,031 | -63,320 | -78,399 |
|
Total Unusual Items
|
12,476 | 9,214 | 8,556 |
|
Total Unusual Items Excluding Goodwill
|
12,476 | 9,214 | 8,556 |
|
Tax Effect of Unusual Items
|
0 | 0 | 0 |
|
Tax Rate, Calculated
|
0.00 | 0.00 | 0.00 |
12/31/2021 - 6/12/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade